Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
23 Jun 2022 04:27 PM
RNS
Result of Annual General Meeting
16 Jun 2022 04:41 PM
RNS
Second Price Monitoring Extn
16 Jun 2022 04:36 PM
RNS
Price Monitoring Extension
31 May 2022 07:00 AM
RNS
Posting of Annual Report and Notice of AGM
16 May 2022 12:00 PM
RNS
AffyXell expands partnership with GenScript ProBio
11 May 2022 07:00 AM
RNS
London Therapeutics headquarters established
06 May 2022 07:00 AM
RNS
Block Listing Application to AIM (update)
28 Apr 2022 01:53 PM
RNS
Block Listing Application to AIM
14 Apr 2022 05:01 PM
RNS
Issue of Equity and Total Voting Rights
14 Apr 2022 11:29 AM
RNS
Issue of Equity and Total Voting Rights
13 Apr 2022 07:00 AM
RNS
AffyXell milestone and increased equity stake
12 Apr 2022 07:00 AM
RNS
Poster presented at the AACR available to download
11 Apr 2022 04:41 PM
RNS
Second Price Monitoring Extn
11 Apr 2022 04:35 PM
RNS
Price Monitoring Extension
11 Apr 2022 02:05 PM
RNS
Second Price Monitoring Extn
11 Apr 2022 02:00 PM
RNS
Price Monitoring Extension
08 Apr 2022 01:57 PM
RNS
Issue of Equity and Total Voting Rights
08 Apr 2022 07:00 AM
RNS
AffyXell partners with Biocytogen and KNTSC
07 Apr 2022 04:31 PM
RNS
Issue of Equity and Total Voting Rights
06 Apr 2022 07:00 AM
RNS
Preliminary Results
30 Mar 2022 04:41 PM
RNS
Second Price Monitoring Extn
30 Mar 2022 04:35 PM
RNS
Price Monitoring Extension
30 Mar 2022 07:00 AM
RNS
Notice of Results and Investor Presentation
29 Mar 2022 07:00 AM
RNS
AVA6000 data poster presentation at AACR
21 Mar 2022 07:00 AM
RNS
Directorate Change
16 Mar 2022 07:00 AM
RNS
Vimian acquires Avacta's Animal Health Division
14 Feb 2022 04:41 PM
RNS
Second Price Monitoring Extn
14 Feb 2022 04:36 PM
RNS
Price Monitoring Extension
07 Feb 2022 04:36 PM
RNS
Price Monitoring Extension
03 Feb 2022 05:26 PM
RNS
Issue of Equity and Total Voting Rights
03 Feb 2022 04:41 PM
RNS
Second Price Monitoring Extn
03 Feb 2022 04:35 PM
RNS
Price Monitoring Extension
03 Feb 2022 07:00 AM
RNS
Dose escalation in the phase I trial of AVA6000
31 Jan 2022 04:41 PM
RNS
Second Price Monitoring Extn
31 Jan 2022 04:36 PM
RNS
Price Monitoring Extension
18 Jan 2022 07:00 AM
RNS
Second pre|CISION Pro-drug Candidate Selected
12 Jan 2022 02:05 PM
RNS
Second Price Monitoring Extn
12 Jan 2022 02:00 PM
RNS
Price Monitoring Extension
10 Jan 2022 07:00 AM
RNS
Update on AffiDX and detection of Omicron variant
04 Jan 2022 11:06 AM
RNS
Second Price Monitoring Extn
04 Jan 2022 11:01 AM
RNS
Price Monitoring Extension
22 Dec 2021 04:26 PM
RNS
Issue of Equity and Total Voting Rights
22 Dec 2021 11:05 AM
RNS
Second Price Monitoring Extn
22 Dec 2021 11:00 AM
RNS
Price Monitoring Extension
22 Dec 2021 07:00 AM
RNS
AffiDX Receives CE Mark for Consumer Self-Testing
16 Dec 2021 07:00 AM
RNS
Issue of Equity and Total Voting Rights
15 Dec 2021 07:00 AM
RNS
AffiDx® lateral flow test detects Omicron variant
15 Dec 2021 07:00 AM
RNS
Change of auditor
29 Nov 2021 07:00 AM
RNS
FDA Approval of IND Application for AVA6000
18 Nov 2021 04:41 PM
RNS
Second Price Monitoring Extn

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100

Latest directors dealings